brisbane cancer conference...‘til late gala dinner, boulevard room, brisbane convention and...

Innovative healthcare through partnerships

brisbane diamantina health partners

Brisbane Cancer Conference

2020

26–27 November 2020Brisbane Convention and Exhibition Centre

CONFERENCE HANDBOOK

Conference Sponsors

Gold Sponsors

Silver Sponsors

Platinum Sponsor

Institution Donations

Pharma and Biotech Donations

Bronze Sponsors

2020 Brisbane Cancer Conference 3

Dear Colleagues,

Welcome to the 7th Annual Brisbane Cancer Conference. With the establishment of the Brisbane Diamantina Health Partners as an NHMRC Advanced Health research and translation Centre, this meeting is an opportunity to draw together cancer researchers in Brisbane and Queensland to advance collaborative efforts in cancer research. The meeting comprises plenary lectures and workshops on recent scientific, technological, nursing and medical advances in the diagnosis and treatment of malignant disease.

On Thursday 26th November the meeting will start with Breast Cancer, Prostate Cancer, Survivorship and Immunotherapy symposia running from 8am–12pm in the morning. There will be satellite symposia at lunch-time followed by plenary lectures from 2–4pm and subsequently workshops in these areas running from 4:30–6:00pm.

The Gala dinner will be held on Thursday evening offering the opportunity to socialise with colleagues from other institutions in the city and from Queensland.

The all-day session on Friday 27th November will include plenary lectures followed by tumour-site specific workshops in the morning and afternoon. A key session will be lectures by Queensland oncology researchers that have contributed to global advances in our understanding of the epidemiology, molecular biology and treatment of malignant disease.

Over 1,000 delegates will attend the event this year demonstrating the value of a truly multi-disciplinary annual Queensland Translational Cancer Conference in Brisbane.

This conference is made possible through the support of the PA Research Foundation and Brisbane Diamantina Health Partners, our many sponsors, the time and effort of the chairs who put the workshops together as well as Therese and the QUT Cancer and Ageing Research Program (CARP) team.

Best wishes for what should be an enjoyable and fulfilling two days.

Yours sincerely,

Professor Ken O’Byrne Consultant Medical Oncologist Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology

Welcome

2020 Brisbane Cancer Conference4

Conference Program

Thursday 26 November 2020Opens 7.00am Registration

Symposia (8.00–12.00)Immuno-oncology (Supported by AstraZeneca) Room P6-8

Chairs: Riccardo Dolcetti, Kate Roberts

8.00 Critical challenges and future perspectives in cancer immunotherapy – Riccardo Dolcetti

8.30 Combination immunotherapies: The way forward? – Kenneth O’Byrne

9.00 Immunotherapy in resistant disease – Marcin Dzienis

9.30 A new approach to prevent skin cancer in organ transplant patients – James Wells

10.00 Morning tea

10.30 PD1 and innate lymphoid cells in melanoma – Gabrielle Belz

10.50 Genomics in immuno-oncology – Venkateswar Addala

11.10 Toxicity in immunotherapy: insights into management and correlation with outcomes – Peter Manders

11.30 Implications for nursing – Monique Richter, Rebecca Kimberley

Survivorship (Supported by Roche) Room P9

Chairs: Ray Chan, Nicolas Hart

Theme: Using a co-design approach to develop referral pathways for health-lifestyle services for cancer survivors 8.00 Introduction – Ray Chan

8:20 Australian Service-Mapping Study – Elizabeth Pinkham

8:35 Evidence on Exercise and Dietary Interventions for Cancer Survivors – Nicolas Hart

8:50 Facilitated Workshop I (Rotation)

10.00 Morning tea

10.30 Facilitated Workshop II (Rotation)

11:10 Discussion (Live Polls) and Conclusion – Nicolas Hart

11:50 Final Remarks – Ray Chan

Prostate Cancer (Supported by Janssen) Room P10-11

Chairs: Ian Vela, Colleen Nelson

8.00 Circulating cell-free nucleic acids: revealing mysteries of metastatic prostate cancer – Arun Azad (ZOOM)

8.30 TheraP results, with a bit on EnzaP and different PSMA tracers – David Pattison

9.15 UpFrontPSMA: A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer – Arun Azad (ZOOM)

9.45 Mucinous adenocarcinoma of the prostate a rare variant – Pat Thomas

10.00 Morning tea

10.30 Role of NRP1 in enzalutamide resistant prostate cancer – Marianna Volpert

10.50 The Dipper Study and prognostic role of PSMA in localised disease – Matt Roberts

11.10 Neuro-endocrine prostate cancer – Brett Hollier

11.30 hSSB1 in prostate cancer: from the molecule, to the bench and into the patient – Laura Croft

11.50 Prostate cancer: clincial trials update – Ian Vela

Breast Cancer (Supported by Novartis) Plaza Auditorium

Chairs: Fiona Simpson, Eliza Whiteside, Jasotha Sanmugarajah

8.00 Chemical Changes in Breast Tissue Non-Invasively Predict Risk of Cancer – Carolyn Mountford

8.25 Connecting the genome to gene function for breast cancer – Stacey Edwards

8.50 Eraser enzymes and Epigenetic re-programming in metastatic breast cancer – Sudha Rao

9.15 The changing role of multidisciplinary teams in the diagnostic breast clinic – Sharyn Donaldson .

9.40 HER2 testing in breast cancer – Cameron Snell

10.00 Morning tea

Chairs: Margot Lehman, Peter Simpson

10.30 Circulating tumour DNA to facilitate precision medicine in breast cancer – Sarah Jane Dawson (ZOOM)

10.55 Breast cancer trials in QLD – Kate Cuff

11.20 Targeting Neuropilin-1 in claudin-low breast cancer – Marianna Volpert

11.40 Cold Atmospheric Plasma Therapy Selectively Targets Triple Negative Breast Cancer Cells – Peiyu (Freda) Wang

DAY1


Conference Program

12.00 Refreshments

Lunchtime sponsored symposia (12.15–1.45) Plaza AuditoriumAstrazeneca: Lung cancer diagnostics

Chairs: Tim Edwards, Caroline Cooper

12.15 Maximising yield for molecular analysis at EBUS TBNA – David Fielding

12.30 Ancillary testing of EBUS samples and case studies from the Molecular MDT – Paul Leo

12.45 Discussion and Q&A

Roche: Advances hepatocellular cancer

Chair: Melissa Eastgate

13.00 Current Treatment Landscape of Hepatocellular Carcinoma – Marnie Wood

13.12 Systemic therapy and recent advances with cancer immunotherapy in HCC: the IMbrave150 Study – Vlad Andelkovic

13.25 Clinical Considerations with the use of Tecentriq+Avastin in HCC: Case study – James O’Beirne

13.35 Panel discussion – Patient characteristics and selection – Safety Management Considerations - IT issues – MDT Approach: considerations – Implementation of the new treatment modality

13.45 Lunch

Plenary Lectures (14.00–16.00) Plaza Auditorium Chairs: Damian Topp, Sunil Lakhani

14.00 Survivorship for patients with neuroendocrine tumours – David Wyld

14.20 QOOL in action: a cancer learning environment for Queensland – Shoni Philpot

14.40 Genomics in melanoma – Felicity Newell

15.00 Precision oncology for breast cancer – Amy McCart Reed

15.20 Genomics and clinical care: the nursing perspective – Kim Alexandra (supported by QUT)

15.40 The MoST trial: where are we and the future? – David Thomas (ZOOM)

16.00 Refreshments

Parallel Workshops (16.30–18.00)GU malignancies Room P6

Chairs: Jeff Goh, David Waugh

16.30 Latest advances in robotic surgery for renal & bladder malignancies – Anojan Navaratnam

16.45 Treatment of small renal masses – SBRT – Charles Lin – Radio Frequency Ablation – Nick Brown (ZOOM)

17.10 Q&A

17.20 Treatment of advanced urothelail cancer & clinical trials update – Harry Gaspar

17.35 Treatment of advanced Renal Cancer Cancer & ongoing clinical trials – Jeff Goh


Big Data Room P8

Chairs: Euan Walpole, Shoni Philpot

Theme: Real world data for quality assurance in patient care and research

16.30 Welcome, introductions and overview – Shoni Philpot

16.40 Natural language processing; a novel approach to determine recurrence for 5 cancer populations – Danica Cossio

16.55 How genomics is being used to influence management of AML – Cameron Curley

17.10 Auditing electronic data: the challenges, ethics and quality assurance – Dan McKavanagh

17.25 Mining the data: measuring optimal care pathways in cancer – Euan Walpole


Thursday 26 November 2020

DAY1


Parallel Workshops (16.30–18.00)Survivorship and Geri-oncology Room P9

Chairs: Darshit Thaker, David Wyld

Title: Geriatric Oncology Services across Queensland: One Aim, Different Approaches

16.30 Introduction: Setting the scene – David Wyld, Darshit Thaker

16.40 Geriatrician view of OncoGeriatric assessment and its impact – Ruth Hubbard

16.50 Oncologist view of OncoGeriatric assessment and its impact – Darshit Thaker

17.00 GeriOnc Service model, its strengths and limitations - MNHHS – Justine Leach, Hermione Wheatley

17.05 GeriOnc Service model, its strengths and limitations - MSHHS representative – Rahul Ladwa, Robyn Berry

17.10 GeriOnc Service model, its strengths and limitations - GCUH representative – Suzanne Allan, Amanda Quennell

17.15 GeriOnc Service model, its strengths and limitations - Townsville Hospital representative - Angeline Khoo, Sally Allen (ZOOM)

17.20 Panel Discussion: Common strengths and service limitations - How can we work together?


Genomics Room P10

Chairs: John Pearson, Paul Leo

Theme: Translation of genomics into the clinic16.30 Predicting responses to chemotherapy – Pascal Duijf

16.48 Genomics and radiomics – Lauren Aoude

17.06 Genomics of PDX models: application to the clinic – Olga Kondrashova

17.24 Post GWAS era and non-coding risk loci for breast cancer genetics – Juliet French

17.42 Classifying actionable mutations in a molecular tumour board: trials and tribulations – Paul Leo

Clinical trials Room P11

Chairs: Adam Stoneley, Suzanne Elliott

Title: Conducting Research During a Pandemic: Lessons Learned and Innovations Introduced The goal of this presentation is to share knowledge between sites about how we have confronted the challenges presented by the prospect of conducting research during a pandemic; what we have done well, what we may need to improve, and what we plan to do moving forward.

16.30 Royal Brisbane & Women’s Hospital – Amy Ives

16.42 Mater Hospital – Julie Cichero

16.54 Gold Coast University Hospital – Elise Sturgeon, Donna Kreuter

17.06 IQVIA – Elizabeth Wilson

17.18 Gallipoli Medical Research Foundation – Rachel Wong

17.30 Princess Alexandra Hospital – Mitchell Peters

17.42 Icon Cancer Centre – Tori Furner

17.54 Discussion

Evening industry symposium (18.15 – 19.00) Plaza AuditoriumIntroduction to genomic platforms18.15 Illumina: Enabling in-house comprehensive genomic profiling of tissue and liquid biopsy samples – Anthony

Beckhouse

18.30 Qiagen: Multimodal PanCancer: The Power of One – Ehsan Nourbakhsh

18.45 Foundation Medicine, Roche: CGP liquid biopsy - how does it complement tissue biopsy? – Nicolas Martin

7.15pm ‘til late

Gala Dinner, Boulevard Room, Brisbane Convention and Exhibition Centre

Thursday 26 November 2020

Conference Program

DAY1


Opens 7.00am Registration

Plenary Lectures (8.00–10.00) Plaza AuditoriumChairs: Fabienne Mackay, Patsy Yates

8.00 Squamous cell skin cancer; an update – Rahul Ladwa

8.20 BANF1 in cancer – Emma Bolderson

8.40 Medicinal cannabis in cancer care: research update – Phillip Good

9.00 State of Science in Exercise Oncology: What’s next for Queensland? – Nicolas Hart

9.20 Children’s Brain Cancer Centre, Brisbane – Tim Hassall

9.40 New innovations in cancer nursing – Leanne Stone

10.00 Refreshments

Parallel Workshops (10.30–12.00)Pharmacy Research & Innovation Roundup Plaza Auditorium

Chair: Dan McKavanagh

10.30 Setting the scene – Dan McKavanagh

10.35 Clinical Trials and Research in Cancer Treatment (RHC) – Liam King

10.50 Compliance with calcium and vitamin D supplementation in patients receiving bone resorptive agents (ICON) – Ashleigh Smith

11.05 Biosimilars - Sustaining the cost of biologics (PAH) – Christine Carrington

11.20 Oral Mucositis Management - MASCC guidelines update and mucositis research (RBWH) – Midori Nakagaki

11.35 Immune-related adverse events with immune checkpoint inhibitors (TPCH) – Thi Nguyen, Sandy Chew

11.50 Q&A and closing remarks

3-D cancer models Room P6

Chairs: Laura Bray, Priyakshi Kalita-de Croft

10.30 Patient derived Glioblastoma organoid models – Ulrich Baumgartner

10.42 Advanced 3D models for cancer drug discovery – Elke Kaemmerer

10.55 Connecting the Greenspan model for avascular tumour growth to experimental data – Ryan Murphy

11.08 iPSC derived cortical organoids – Romal Stewart

11.20 Prostate stromal cells regulate early angiogenesis in a bioengineered PCa model – Anna Jaeschke

11.32 3D spheroids from renal cell carcinoma cell lines and primary cultures to investigate novel therapies – Aaron Urquhart

11.45 Development of a patient-derived osteoblast/osteoclast 3D in vitro model for the study of breast cancer bone metastases – Valerie Nitschke

Gynae-oncology Room P7

Chairs: John Hooper, Kathryn Middleton

10.30 PARP inhibitors in ovarian cancer; Immunotherapy and CD4/6 Inhibitors in endometrial cancer – Kathryn Middleton

10.45 Variation in care and survival, aetiology and risk factors to improve ovarian cancer outcomes in Australia – Penny Webb

11.00 CRISPR for cervical cancer treatment and detection – Nigel McMillan

11.15 Molecular classification impact on outcomes of adjuvant therapy for endometrial cancer – Pam Pollock

11.30 SASH1 in ovarian cancer – Josh Burgess

11.45 Uterine serous papillary carcinoma BRCA1/2 study – Mohammad Al-Shinnag

Friday 27 November 2020

Conference Program

DAY2


Parallel Workshops (10.30–12.00)Brain tumours Room P8

Chairs: Mark Pinkham, Brian Day, Sarah Olsen, Zarnie Lwin

10.30 Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for Medulloblastoma – Laura Genovesi

10.45 Circulating tumour cells and glioma – Sudha Rao

11.00 Sugar metabolism and gliomas – Selena Bartlett

11.15 Theranostics for gliomas – Zachary Houston

11.30 Overview of imaging, therapy and supportive CNS clinical trials in Brisbane – Mark Pinkham

Immuno-oncology Room P9

Chairs: Michelle Wykes, Corey Smyth

10.30 Translational research – getting from bedside to the bench – Melissa Eastgate

10.45 AI-driven Discovery Analytics for Tumour Immunology – Sriganesh Srihari

11.00 Novel PDL1 molecular switch regulates transcriptional program orchestrating immunotherapy resistance – Sudah Rao

11.15 PD-L2 therapy – Rebecca Faleiro

11.30 Augmenting immunotherapy in cancer – Priscila Oliviera Da Lima

11.45 ‘Off-the-shelf’ allogeneic T-cell therapy for the treatment of multiple Epstein–Barr virus-associated cancers – Debottam Sinha

11.55 Closing remarks

Thoracic Malignancies (supported by Roche) Room P10

Chairs: Michelle Murphy, Bryan Chan

10.30 Screening for lung cancer in Australia – Fraser Brims (ZOOM)

10.40 Luckistars program – Nic Waddell

10.50 Breath test diagnostics: potential in lung cancer – David Fielding

11.00 Genomics in lung cancer – Sanjay Dutta

11.10 Reversing systemic therapy resistance in NSCLC – Bahar Sahin

11.20 Potential clinical utility of combining CTCs and ctDNA for prognosis of NSCLC – Joanna Kapeleris

11.30 Nanostring digital spatial analysis in the assessment of lung cancer – James Monkman

11.40 COMMD family in lung cancer – Amila Suraweera

11.50 ctDNA in selecting patients for adjuvant lung cancer trials: are we there yet? – Kenneth O’Byrne

Hepato-biliary cancer Room P11Chairs: Darrell Crawford, Barbara Leggett, Vladimir Andelkovic10.30 Diagnosis, Staging and Local Treatment Options for Patients with Hepatocellular Carcinoma – Marnie Wood

10.45 Systemic Therapy for Hepatocellular Carcinoma – Vladimir Andelkovic

11.00 Treatment-induced hepatic stellate cell activation in liver cancer – Haolu Wang

11.15 Epithelial to mesenchymal transition and immune checkpoint inhibitors in liver cancer – Ritu Shrestha

11.30 Screening for pancreatic cancer in high risk individuals – Benedict Devereaux

11.45 Advances and trials in pancreatic cancer – Warren Joubert

12.00 Lunch

Plenary Lectures (12.30–14.00) Plaza AuditoriumChairs: Scott Bell, Paul Clarke

12.30 Moving beyond measurement: ePROMs (electronic patient reported outcome measures) and PREMs (patient reported experience measures) to inform cancer care – Laurelie Wishart

12.52 Human papilloma virus and Head and Neck cancer – Sandro Porceddu

13.14 Improving anti-tumour drug targeting – Fiona Simpson

13.36 Melanoma 2020 – Victoria Atkinson

14.00 Refreshments


Conference Program

DAY2


Parallel Workshops (14.30–16.00)Haematology Room P6

Chair: Colm Keane

Theme: CAR-T and Cellular/Immune therapies in Brisbane: Current Status and Future Directions 14.30 Point-of Care Manufacture of CAR-T cells – Siok Tey

14.55 Upcoming Cellular and Immune therapy Trials for Aggressive Lymphoma in Brisbane – Colm Keane

15.20 Setting up a CAR T unit – Creating a “GO-CAR T” not a “CRASH-CAR T – Jason Butler

15.45 Discussion and closing remarks

Palliative Care Room P7

Chairs: Ben Gunawan, Phillip Good

14.30 Future stories - investigating the potential of young people and their community of carers with virtual reality (VR) experiences in hospital contexts – a pilot study – Anthony Herbert

14.45 Changing perceptions of and barriers to medicinal cannabis in palliative care: A literature review – Amelia Nixon

15.00 Development of quality indicators in palliative and end of life care – Elise Button

15.15 Nerve blocks for the palliation of pain in cancer patients – Navid Amirabadi

15.30 How do healthcare professionals communicate about death and dying? – Emily Neate

15.45 Opioids for pain management in palliative care - does genetics play a role in inter-patient variability? – Alison Haywood

GI malignancies Room P8

Chairs: Vicki Whitehall, Nick Lutton, Matthew Burge

14.30 Genomic Studies in Lower GI Cancers: Therapeutic Opportunities? – Kate Roberts

14.40 Immunophenotyping to Predict Colorectal Cancer Survival – Jennifer Borowsky

14.50 Targeting CDCP1 in advanced colorectal cancer – Nick Lyons (ZOOM)

15.00 Recent Colorectal Cancer Clinical Trials and Impact on Practice – Matt Burge

15.10 Discussion

15.20 Current Approaches to Colorectal Surgery – David Clark

15.30 Advances in Robotic Colorectal Surgery – Andrew Stevenson

15.40 Current Approaches to Colorectal Metastasectomy – Richard Bryant

15.50 Discussion

Liquid biopsies Room P9

Chair: Matt Trau

14.30 Liquid biopsy for Barrett’s oesophagus surveillance – Michelle Hill

14.45 Multi-protein exosome signature predicts the presence of cancer – Richard Lobb

15.00 Advancing nanomaterial-based systems towards circulating biomarker detection for precision oncology – Junrong Li

15.15 Multiplexed serpentine microchannels for high throughput sorting of disseminated tumor cells from malignant pleural effusion – Jun Zhang

15.30 Salivary diagnostic: enabling precision medicine in cancer – Xi Zhang

Melanoma and skin cancer Room P10

Chairs: Nikolas Haass, Helmut Schaider, Jacinta Simmons

14.30 Parameterising mathematical models of melanoma invasion through a sequence of experiments – Alexander Browning

14.40 The POT1 tumour predisposition syndrome – Vaishnavi Nathan

14.50 Human CD141+ dendritic cells (cDC1) can be targeted to enhance efficacy of anti-PD-1 in a humanized mouse model of melanoma – Liam O’Brien

15.00 CLEC12B is a tumor-suppressor gene in melanoma that regulates STAT activation – Laura Sormani Le Bourhis

15.10 Role of Growth Hormone Receptor Signalling in Melanoma Progression, Therapeutic Resistance, and Immune Evasion – Andrew Brooks

15.20 Epigenetic reactivation of LC3B induces melanoma cell death and predict response to checkpoint inhibitor blockade – Greg Kelly

15.30 Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma – Alain Wuethrich

15.40 Targeting DNA Damage Response Defects in Melanoma – Madushan Fernando

15.50 Beta-hairpin peptides kill drug-resistant metastatic melanoma – Sonia Henriques


Conference Program

DAY2


Parallel Workshops (14.30–16.00)Breast cancer Room P11

Chairs: Juliette French, Pascal Duijf

14.30 Drug-Induced Epithelial-Mesenchymal Transition in Breast Cancer by a Microfluidic Surface-Enhanced Raman Spectroscopy Immunoassay – Zhen Zhang

14.48 The Proteomic and Transcriptomic Landscape of Breast Cancer Extracellular Vesicles – Rebecca Lane

15.06 A nanomedicine approach to treat breast cancer brain metastases – Malcolm Lim

15.24 Clinical Implications of Hook-Related Protein Expression in Hormone-Receptor Positive Breast Cancer – Emma Karlsen

15.42 CDCA3 in breast cancer – Mark Adams

Head and neck cancer (supported by Lilly Oncology) AuditoriumChairs: Rahul Ladwa, Chris Perry14.30 Antigen-specific immunotherapy for HPV+ head and neck cancer - concepts, development, clinical translation –

Janin Chandra

14.38 A new way to treat and image adenoid cystic carcinoma – Benedict Lum

14.46 PSMA: from prostate cancer to adenoid cystic carcinoma – James Nightingale

14.54 Tongue base mucosectomy and TORS for Head and neck SCC – Sam Dowthwaite

15.02 Internal and External Head and neck lymphoedema and swallow – Elizabeth Ward

15.10 Salivary exosomes to detect oral cancer – Kai Tang

15.18 miRNA as biomarkers for HPV driven oropharyngeal cancers – Chameera Ekanayake Weeramange

15.26 Proteomics of HPV-positive oropharyngeal cancer: Targeting non-responders – Chris Jackson

15.34 Orbit-preserving surgery for V1 perineural spread – Lachlan Crawford

15.42 Advanced periauricular SCC with temporal bone involvement – Michael Schachtel

15.50 Speech pathology service enhancement for people with HNC in regional and remote areas – Jasmine Foley

16.00 Refreshments

Plenary session: focus on the future (16.15–17.15) Plaza Auditorium Chairs: David Bunker

16.15 Brisbane Diamantina Health Partners – David Bunker

Technologies advancing our understanding of the molecular biology of malignant disease16.25 Nanostring Digital Spatial Profiling in Cancer Research – Arutha Kulasinghe

16.45 10XGenomics – Quan Nguyen

17.05 Q&A

17.15 – 18.00 Wine and cheese


Conference Program

DAY2

112019 Brisbane Cancer Conference

Venue Floor Plans

Dock 1

Hall 1 Concourse Great Hall Concourse

Great Hall Dock

Exhibition Hall 1 Great Hall

Q3

Q4

Q2

Q1

Operable Wall

Operable Wall

Door 4

Door 1 Door

2

Door 3

F1

MerivalesCafe & Bar

MainFoyer

Main Entrance

Terr

ace

Board Room 1

Board Room 2

Convenors 1

Lifts

Tasting Room

Escalators

Stairs

CarLift

EX

HIB

ITION

HA

LLS 2-4

MERIVALE STREET

Exhibition Hall 4

Exhibition Hall 3

Exhibition Hall 2

Exhibition Hall 1

M10

M9 M8 M7 M6 M5

Speakers Presentation

Centre

Door 9

Q3

Q4 Q1

Q2

Great Hall

Great Hall Mezzanine ConcourseDoor 5

Door 7

Door 8

Door 6

Mezzanine Foyer

Escalators

Escalators

M4 M3

M2

M1Mezz Cafe

1

Mezz Cafe

2

Ramp

StairsLifts

Bar

Lifts

CarLift

VIPSuite

Foyer

Plaza Ballroom FoyerTo BCEC onMerivale St

Plaza BallroomPlaza Ballroom Plaza Terrace Room

Plaza Ballroom

Foyer

Plaza Terrace (outdoors)

Plaza Foyer

PTR ConcourseCar Lift

Plaza Gallery Escalators

Lifts

P5

P4

P3

P2

P1

Stairs

Plaza Ballroom Concourse

Plaza AuditoriumFoyer

Plaza Auditorium

Stairs to Sky Level

Lobby

RegistrationPlaza Central Terrace

Lift

LiftLift

Ballroom Dressing

Room

P6P7P8P9P10P11

Bar

Green Room

Bar

Plaza North Terrace

Foyer



Plaza Ballroom

Foyer


Plaza Foyer



Lifts

P5

P4

P3

P2

P1

Stairs



Plaza Auditorium

Stairs to Sky Level

Lobby


Lift

LiftLift

Ballroom Dressing

Room

P6P7P8P9P10P11

Bar

Green Room

Bar

Plaza North Terrace

S1S1Foyer

Sky Bridge

Sky RoomSky Foyer

Sky Terrace

Stairs to Plaza Level

Lift

Bar

LiftLift

Lift

Lift

Loading

Retail

Grey Street Foyer

Parent

Cloak Room

OlioCafe & Bar

Bar

Olio Terrace

Russ

ell W

alkRetail

RetailRetail

Lift

BoulevardAuditorium

Boulevard Auditorium Foyer

BoulevardRoom

B1B2B3Lobby

Lift

Lift

Lift

Boulevard Room Foyer

Boulevard North Terrace

Boulevard Central TerraceRegistration

Bar

LoadingGreen Room

Bar

Plaza(Grey Street)

Sky(Grey Street)

Concord(Grey Street)

Plaza(Merivale Street)

Boulevard(Grey Street)

Mezzanine(Merivale Street)

Arbour(Grey Street)

Foyer(Merivale Street)

Exhibition (Merivale Street)

Ground(Grey Street)

Train Parking

Parking

Bus

Lower Foyer(Merivale Street)

Lower Level of BoulevardAuditorium

Speakers Presentation Centre

Lift

Backstage

GreenRoom

ArbourSpeakers Lounge

Lobby

Arbour Boardroom

Lift

Lift

Arbour Foyer

Lift

BarArbour LoungeA2

Lift

A1

Lower Level of Plaza

Auditorium

SpeakersPresentation Centre

Lift

Green Room

Concord Speakers Lounge

Lobby

Concord Boardroom

Lift

Lift

GREY STREET CITY/CBD SOUTH BANK/RIVER

MERIVALE STREET WEST END

ME

LBO

UR

NE

ST

RE

ET G

LEN

ELG

ST

RE

ET

CITY/CBD

SOUTH BANK PRECINCT

WEST END

Dock 1


Great Hall Dock


Q3

Q4

Q2

Q1

Operable Wall

Operable Wall

Door 4

Door 1 Door

2

Door 3

F1

MerivalesCafe & Bar

MainFoyer

Main Entrance

Terr

ace

Board Room 1

Board Room 2

Convenors 1

Lifts

Tasting Room

Escalators

Stairs

CarLift

EX

HIB

ITIO

N H

AL

LS

2-4

MERIVALE STREET

Exhibition Hall 4

Exhibition Hall 3

Exhibition Hall 2

Exhibition Hall 1

M10

M9 M8 M7 M6 M5


Centre

Door 9

Q3

Q4 Q1

Q2

Great Hall


Door 7

Door 8

Door 6

Mezzanine Foyer

Escalators

Escalators

M4 M3

M2

M1Mezz Cafe

1

Mezz Cafe

2

Ramp

StairsLifts

Bar

Lifts

CarLift

VIPSuite

Foyer



Plaza Ballroom

Foyer


Plaza Foyer



Lifts

P5

P4

P3

P2

P1

Stairs



Plaza Auditorium

Stairs to Sky Level

Lobby


Lift

LiftLift

Ballroom Dressing

Room

8P 7P 6PP9P10P11

Bar

Green Room

Bar

Plaza North Terrace



Plaza Auditorium

Stairs to Sky Level

Lobby


Lift

LiftLift

8P 7P 6PP9P10P11

Bar

Green Room

Bar

Plaza North Terrace

S1S1Foyer

Sky Bridge

Sky RoomSky Foyer

Sky Terrace


Lift

Bar

LiftLift

Lift

Lift

Loading

Retail

Grey Street Foyer

Parent

Cloak Room

OlioCafe & Bar

Bar

Olio Terrace

Russ

ell W

alkRetail

RetailRetail

Lift

BoulevardAuditorium


BoulevardRoom

3B 2B 1BLobby

Lift

Lift

Lift




Bar

LoadingGreen Room

Bar

Plaza(Grey Street)

Sky(Grey Street)





Arbour(Grey Street)



Ground(Grey Street)

Train Parking

Parking

Bus




Lift

Backstage

GreenRoom


Lobby

Arbour Boardroom

Lift

Lift

Arbour Foyer

Lift

BarArbour LoungeA2

Lift

A1


Auditorium


Lift

Green Room


Lobby

Concord Boardroom

Lift

Lift



GLE

NE

LG S

TR

EE

T

CITY/CBD

SOUTH BANK PRECINCT

WEST END

Dock 1


Great Hall Dock


Q3

Q4

Q2

Q1

Operable Wall

Operable Wall

Door 4

Door 1 Door

2

Door 3

F1

MerivalesCafe & Bar

MainFoyer

Main Entrance

Terr

ace

Board Room 1

Board Room 2

Convenors 1

Lifts

Tasting Room

Escalators

Stairs

CarLift

EX

HIB

ITIO

N H

AL

LS

2-4

MERIVALE STREET

Exhibition Hall 4

Exhibition Hall 3

Exhibition Hall 2

Exhibition Hall 1

M10

M9 M8 M7 M6 M5


Centre

Door 9

Q3

Q4 Q1

Q2

Great Hall


Door 7

Door 8

Door 6

Mezzanine Foyer

Escalators

Escalators

M4 M3

M2

M1Mezz Cafe

1

Mezz Cafe

2

Ramp

StairsLifts

Bar

Lifts

CarLift

VIPSuite

Foyer



Plaza Ballroom

Foyer


Plaza Foyer



Lifts

P5

P4

P3

P2

P1

Stairs



Plaza Auditorium

Stairs to Sky Level

Lobby


Lift

LiftLift

Ballroom Dressing

Room

8P 7P 6PP9P10P11

Bar

Green Room

Bar

Plaza North Terrace



Plaza Auditorium

Stairs to Sky Level

Lobby


Lift

LiftLift

8P 7P 6PP9P10P11

Bar

Green Room

Bar

Plaza North Terrace

S1S1Foyer

Sky Bridge

Sky RoomSky Foyer

Sky Terrace


Lift

Bar

LiftLift

Lift

Lift

Loading

Retail

Grey Street Foyer

Parent

Cloak Room

OlioCafe & Bar

Bar

Olio Terrace

Russ

ell W

alkRetail

RetailRetail

Lift

BoulevardAuditorium


BoulevardRoom

3B 2B 1BLobby

Lift

Lift

Lift




Bar

LoadingGreen Room

Bar

Plaza(Grey Street)

Sky(Grey Street)





Arbour(Grey Street)



Ground(Grey Street)

Train Parking

Parking

Bus




Lift

Backstage

GreenRoom


Lobby

Arbour Boardroom

Lift

Lift

Arbour Foyer

Lift

BarArbour LoungeA2

Lift

A1


Auditorium


Lift

Green Room


Lobby

Concord Boardroom

Lift

Lift



GLE

NE

LG S

TR

EE

T

CITY/CBD

SOUTH BANK PRECINCT

WEST END

Plaza Level

Boulevard Level

3Janssen

6P

7P

8P

9P

01P

11P

PLAZA AUD

ITORIU

M FO

YER

MEETIN

G A

REA

MEETIN

G A

REA

T417ICON

G

roup

16TRI15

Am

gen

14N

euvohealth

13N

anostring/Biostrategy

T312

Astellas

11Ipsen

10Illum

ina

T29Merck

8Servier7Bayer

T1

5MSD

2BMS

1A

strazeneca

6N

ovartis

4Pfizer

Astrazeneca 1

BMS 2

Janssen 3

Pfizer 4

MSD 5

Novartis 6

Bayer 7

Servier 8

Merck 9

Illumina 10

Ipsen 11

Astellas 12

Nanostring/Biostrategy 13

Neuvohealth 14

Amgen 15

Translational Research Institute 16

ICON Group 17

Qiagen T1

Mundipharma T2

Pierre-Fabre T3

Teva T4

Sponsor Floor Plan

brisbane cancer conference...‘til late gala dinner, boulevard room, brisbane convention and...

Documents